Free Trial

Nuvalent (NUVL) Stock Forecast & Price Target

$78.65
+0.66 (+0.85%)
(As of 07/12/2024 ET)

Nuvalent - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$96.33
22.48% Upside
High Forecast$115.00
Average Forecast$96.33
Low Forecast$42.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$96.33$90.78$90.00$44.50
Forecasted Upside22.48% Upside23.94% Upside17.50% Upside24.41% Upside
Get Nuvalent Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.

NUVL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NUVL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nuvalent Stock vs. The Competition

TypeNuvalentMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.71
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside22.48% Upside994.16% Upside9.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$103.00 ➝ $115.00+51.88%
5/17/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$99.00+36.29%
4/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$97.00+50.48%
4/1/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
4/1/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$69.00 ➝ $110.00+46.49%
3/6/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$68.00 ➝ $98.00+16.43%
2/28/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$93.00 ➝ $102.00+15.45%
2/28/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$99.00+11.25%
2/23/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$105.00+26.16%
8/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$42.00-5.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:03 AM ET.

NUVL Forecast - Frequently Asked Questions

What is Nuvalent's forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Nuvalent is $96.33, with a high forecast of $115.00 and a low forecast of $42.00.

Should I buy or sell Nuvalent stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last twelve months. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares.

Does Nuvalent's stock price have much upside?

According to analysts, Nuvalent's stock has a predicted upside of 28.01% based on their 12-month stock forecasts.

What analysts cover Nuvalent?

Nuvalent has been rated by research analysts at Jefferies Financial Group, Stifel Nicolaus, and Wedbush in the past 90 days.

Do Wall Street analysts like Nuvalent more than its competitors?

Analysts like Nuvalent more than other "medical" companies. The consensus rating score for Nuvalent is 2.90 while the average consensus rating score for "medical" companies is 2.71. Learn more on how NUVL compares to other companies.


This page (NASDAQ:NUVL) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners